In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly's Oncology Focus

Executive Summary

On October 6, Eli Lilly & Co. became the latest pharmaceutical company to jump on the cancer bandwagon, with its $6.5 billion acquisition of ImClone Systems Inc.The deal gives Lilly the royalty stream to one marketed product-cetuximab (Erbitux), plus five additional clinical stage compounds, many of which are biologics. The problem is many of the candidate drugs face stiff competition--and the pharma has severely depleted its cash holdings to get the deal signed.
Advertisement

Related Content

Bristol-Myers's Grand Ambitions in Oncology
Bristol-Myers's Grand Ambitions in Oncology
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2008
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2008
The Golden Age in Cancer Medtech Investing
The Golden Age in Cancer Medtech Investing
Credit Woes Hit Pharma
Credit Woes Hit Pharma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel